Table 3.
Univariate analysis of predictors of progression-free survival (PFS) and overall survival (OS) in CR patients with DLBCL.
| Variable | PFS |
OS |
||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |||
| Gender | ||||||||
| Male vs female | 0.893 | 0.618 | 1.289 | 0.545 | 1.028 | 0.651 | 1.623 | 0.905 |
| International Prognostic Index (IPI) | ||||||||
| Low/low-intermediate/intermediate-high/high | 1.930 | 1.628 | 2.287 | < 0.001 | 2.210 | 1.790 | 2.728 | < 0.001 |
| Revised International Prognostic Index (R-IPI) | ||||||||
| Very good/good/poor | 2.467 | 1.861 | 3.272 | < 0.001 | 3.139 | 2.179 | 4.524 | < 0.001 |
| National Comprehensive Cancer Network (NCCN)-IPI | ||||||||
| Low/low-intermediate/ Intermediate-high/high |
2.081 | 1.631 | 2.656 | < 0.001 | 2.397 | 1.784 | 3.221 | < 0.001 |
| Cell of origin | ||||||||
| GCB vs non-GCB | 0.557 | 0.346 | 0.896 | 0.016 | 0.701 | 0.402 | 1.225 | 0.212 |
| Double BCL-2/MYC expression | ||||||||
| Positive vs negative | 1.971 | 1.260 | 3.082 | 0.003 | 2.284 | 1.302 | 4.007 | 0.004 |
| Ki-67 > 80% | ||||||||
| Yes vs no | 0.875 | 0.569 | 1.343 | 0.541 | 1.366 | 0.792 | 2.356 | 0.262 |
| BCRs related mutations | ||||||||
| Positive vs negative | 2.239 | 1.251 | 4.008 | 0.007 | 1.651 | 0.818 | 3.329 | 0.162 |
| TLRs related mutations | ||||||||
| Positive vs negative | 1.712 | 0.874 | 3.352 | 0.117 | 1.581 | 0.688 | 3.638 | 0.281 |
| TNFR related mutations | ||||||||
| Positive vs negative | 1.337 | 0.649 | 2.753 | 0.431 | 1.662 | 0.753 | 3.669 | 0.209 |
| Additional Rituximab | ||||||||
| Yes vs no | 0.811 | 0.564 | 1.166 | 0.259 | 0.836 | 0.533 | 1.312 | 0.436 |